BiotechTube

Gemcitabine + Cisplatin + Durvalumab

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bile Duct Cancer

Conditions

Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Metastatic Intrahepatic Cholangiocarcinoma

Trial Timeline

Feb 13, 2024 → Dec 1, 2027

NCT ID
NCT05655949

About Gemcitabine + Cisplatin + Durvalumab

Gemcitabine + Cisplatin + Durvalumab is a phase 2 stage product being developed by AstraZeneca for Bile Duct Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05655949. Target conditions include Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable.

What happened to similar drugs?

0 of 3 similar drugs in Bile Duct Cancer were approved

Approved (0) Terminated (0) Active (3)
🔄cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
🔄Cholic acidMirum PharmaceuticalsPhase 3
🔄Cholic AcidMirum PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06440993Phase 2Recruiting
NCT05655949Phase 2Recruiting

Competing Products

13 competing products in Bile Duct Cancer

See all competitors
ProductCompanyStageHype Score
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
40
exatecan mesylateDaiichi SankyoPhase 2
35
IL-10MerckPhase 2
27
aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracilMerckPhase 2
35
LJN452 + Placebo to LJN452NovartisPhase 2
35
RegorafenibBayerPhase 2
32
Gemcitabine + Cisplatin + SorafenibBayerPhase 2
32
A3384IpsenPhase 2
32
CabozantinibExelixisPhase 2
32
Cholic acidMirum PharmaceuticalsPhase 3
37
CholbamMirum PharmaceuticalsPre-clinical
27
Cholic AcidMirum PharmaceuticalsPhase 3
37
GM-CT-01 + 5-FluorouracilGalectin TherapeuticsPhase 2
17